Enliven Therapeutics (ELVN): Analysts Target $75, Implying +46% Upside

Key Takeaways

• The central target in this analysis is $75, based on the arithmetic mean of individual, verified analyst price targets.
• Shares recently traded near $51, implying a required move of roughly 46% to reach $75 — a substantial, though not extreme, climb.
• Current analyst targets cluster between roughly $69 and $82, with a consensus rating of Strong Buy.
• The strongest support comes from promising ELVN-001 data and a large cash position of about $884 million.
• The biggest risks are clinical and regulatory uncertainty, competition in CML, and a valuation that has already re-rated sharply.
• For more detail on the company, explore its Major News and Today's Price Move, plus dedicated Forecast and Earnings pages.
• Interested in automated stock analysis? Explore Trending AI Robots.

Analyst Targets and the Consensus View

ELVN carries a Strong Buy consensus, with individual price targets that have been raised repeatedly through 2026 as the company reported updated ELVN-001 data and strengthened its balance sheet. Reviewing current, attributable targets — Stifel Nicolaus at $82, Barclays at $78, J.P. Morgan at $75, H.C. Wainwright at $73, Mizuho at $73, Morgan Stanley at $70, and JonesTrading at $70 — produces an arithmetic mean near $74, which rounds to a clean $75 central target. Depending on the data provider, roughly ten to fourteen analysts cover the name, with the latest range spanning about $69 to $82.

The clustering of targets is notable: nearly every firm is at Buy or Overweight, and the spread is relatively narrow for a clinical-stage biotech. The bullish stance reflects a shared view that ELVN-001 could become a meaningful, differentiated treatment in a large CML market. The dispersion between $69 and $82 mainly reflects differing assumptions about how quickly the drug advances and how much market share it can capture, rather than fundamental disagreement about the science. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where ELVN Stands Today and the Path to Target

At a recent price near $51.20, reaching $75 would require a gain of about 46%, which qualifies as a substantial move. The shares have already been volatile: they rose more than 200% year-to-date in 2026 on positive clinical data before pulling back from a 52-week high around $62. The path toward $75 would most plausibly run through further positive ELVN-001 readouts, a successful transition into later-stage trials, and continued analyst target increases — not through current financial results, since the company is pre-revenue and reporting net losses.

Bullish Drivers Behind the Target

• ELVN-001 differentiation: analysts cite the drug's potential as a best-in-class or broadly usable CML therapy, a key driver behind the 2026 rerating.
• Balance-sheet strength: roughly $884 million in cash as of September 30, 2026, funds development without near-term financing pressure.
• Analyst momentum: repeated target increases (for example, Stifel from $60 to $82 and Mizuho from $45 to $73) signal growing conviction.
• Large addressable market: CML is a multibillion-dollar global opportunity with room for a new, differentiated agent.

Risks to Consider

• Clinical and regulatory risk: as a pre-revenue company, disappointing trial data or regulatory setbacks could sharply de-rate the stock.
• Competition: established CML therapies and emerging rivals could limit ELVN-001's commercial potential.
• Valuation: with a market capitalization near $3.8 billion and no sales, much of the opportunity may already be priced in.
• Execution and dilution risk: advancing trials will keep expenses high, and future equity raises could pressure existing shareholders.

Technical Picture and Market Structure

The stock's 52-week range of roughly $15 to $62 highlights both the scale of the 2026 advance and the recent pullback. The $62 area stands out as a major resistance level representing the prior high, while the $44–$45 zone served as a consolidation base before the recent bounce above $50. The $50 mark is a psychological level that has been reclaimed; a sustained hold above it could keep the uptrend intact, while a breakdown below the mid-$40s would suggest weakening structure. These levels matter because a move toward $75 would require first clearing the $62 high and then establishing new ground. From what I see, the technical setup supports watching for a sustained break higher.

What to Watch Next

Analyst price targets typically reflect a roughly 12-month research horizon, though the exact period varies by firm. Because ELVN is driven by clinical milestones, investors should watch upcoming ELVN-001 data presentations and trial updates, the company's quarterly reports for cash-burn and runway commentary, and any analyst target revisions or rating changes. Regulatory developments and competitive data from rivals in CML will also shape the target's achievability. I’m watching this closely as the next data readouts could shift the picture.

Wrapping Up

The $75 central target reflects the mean of current analyst price targets, which cluster tightly between roughly $69 and $82 amid a Strong Buy consensus. Reaching it would require a substantial gain of about 46% from recent levels near $51. The bull case rests on ELVN-001's differentiation, a large CML opportunity, and a fortified balance sheet, while the bear case centers on clinical uncertainty, competition, and an already-elevated valuation. The key upcoming catalysts — clinical data, cash-burn updates, and analyst revisions — will determine whether that $75 level becomes realistic or remains aspirational.

Using AI Tools in My Research

In my own process, I often turn to Tickeron's AI Daily Buy/Sell Signals for a different perspective on names like this. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a catalyst-driven stock such as ELVN, it can surface timely signals that complement traditional analysis and help monitor how sentiment evolves around clinical milestones.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume